Spero Therapeutics
176 articles about Spero Therapeutics
-
Spero Therapeutics Awarded up to an Additional $12.9 Million by BARDA to Support the Development of Orally Administered Tebipenem Pivoxil in Pediatric Patients
1/19/2022
Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that the Company and the Biomedical Advanced Research and Development Authority (BARDA) are expanding their existing partnership to develop tebipenem as a treatment for complicated urinary tract infections (cUTI).
-
Clinical Catch-Up: January 3-7
1/10/2022
The biopharma industry has started 2022 with plenty of clinical trial news. Here’s a look. -
Spero Therapeutics Announces Lifting of FDA Clinical Trial Hold on SPR720
1/4/2022
Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Phase 2 trial of SPR720, Spero’s investigational oral product candidate being developed for nontuberculous mycobacterial (NTM) disease.
-
The FDA decided to lift the hold for its Phase IIa trial of SPR720 after Spero submitted a comprehensive analysis from the NHP toxicology study.
-
Today, the FDA approved two new drug applications. One is for Spero's tebipenem HBr oral tablets and the second is CStone's IND application for CS5001.
-
Spero Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections including Pyelonephritis
1/3/2022
Spero Therapeutics, Inc., announced that the U.S. Food and Drug Administration has granted Priority Review designation and confirmed the acceptance for substantive review of the New Drug Application seeking approval for tebipenem HBr oral tablets for treatment in adult patients with complicated urinary tract infections, including acute pyelonephritis, caused by susceptible microorganisms.
-
Spero Therapeutics to Present at Upcoming Investor Conferences
11/17/2021
Spero Therapeutics, Inc. today announced that Ankit Mahadevia, M.D. will present and be available for one-on-one meetings at the Piper Sandler 33rd Annual Virtual Healthcare Conference and the 4th Annual Evercore ISI HealthCONx Conference.
-
Spero Therapeutics Announces Third Quarter 2021 Operating Results and Provides Business Update
11/10/2021
Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced financial results for the third quarter ended September 30, 2021, and provided a business update.
-
Spero Therapeutics to Provide Business Update and Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021
11/3/2021
Spero Therapeutics, Inc. today announced that it will host a conference call and live audio webcast on Wednesday, November 10, 2021, at 4:30 p.m. ET to report its third quarter 2021 financial results
-
Spero Therapeutics Submits New Drug Application to U.S. FDA for Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections including Pyelonephritis
10/28/2021
Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced the submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA), seeking approval for tebipenem HBr tablets for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible microorganisms.
-
Spero Therapeutics Appoints Kathleen Tregoning to its Board of Directors
10/12/2021
Spero Therapeutics, Inc. today announced the appointment of Kathleen Tregoning to its Board of Directors.
-
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 01, 2021
10/1/2021
Spero Therapeutics, Inc. announced that on September 30, 2021, the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 12,900 shares of its common stock to three new employees under the Spero Therapeutics, Inc.
-
Spero Therapeutics Enters Into a Non-Dilutive Revenue Interest Financing Agreement With HealthCare Royalty Partners® for Up to $125 Million
9/30/2021
Spero Therapeutics, Inc., a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, announced that it has entered into a revenue interest financing agreement with HealthCare Royalty Partners® for up to $125 million.
-
Spero Therapeutics to Present Data at IDWeek 2021
9/16/2021
Spero Therapeutics, Inc. today announced 23 data presentations at the Infectious Disease Society of America (IDSA) IDWeek TM 2021, taking place virtually from September 29 – October 3, 2021.
-
Spero Therapeutics to Present at Three Upcoming Investor Conferences
9/7/2021
Spero Therapeutics, Inc. today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will present and be available for virtual one-on-one meetings at the H.C. Wainwright 23rd Annual Global Investment Conference
-
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 31, 2021
8/31/2021
Spero Therapeutics, Inc. announced that on August 31, 2021, the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 98,300 shares of its common stock to 7 new employees under the Spero Therapeutics, Inc.
-
Spero Therapeutics Announces Second Quarter 2021 Operating Results and Provides Business Update
8/5/2021
Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments in areas of high unmet need, involving multi-drug resistant bacterial infections and rare diseases, today announced financial results for the second quarter ended June 30, 2021, and provided a business update.
-
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 30, 2021
7/30/2021
Spero Therapeutics, Inc. announced that on July 30, 2021, the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 114,600 shares of its common stock to ten new employees under the Spero Therapeutics, Inc.
-
Spero Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results on Thursday, August 5, 2021
7/29/2021
Spero Therapeutics, Inc. announced that it will host a conference call and live audio webcast on August 5, 2021, at 4:30 p.m. ET to report its second quarter 2021 financial results and provide an update on its business and pipeline.
-
Spero Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference
7/7/2021
Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will give a corporate presentation and be available for virtual one-on-one meetings at the Ladenburg Thalmann Healthcare Conference,